Inhibikase Therapeutics (IKT) vs Rocket Pharmaceuticals (RCKT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Inhibikase Therapeutics (IKT) has outperformed Rocket Pharmaceuticals (RCKT) over the past year, gaining 18.7% versus a loss of 30.2%. Over five years, IKT leads with a -83.0% price change compared with -90.8% for RCKT. Rocket Pharmaceuticals is the larger company by market cap ($281.0 million vs $274.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IKT | RCKT |
|---|---|---|
| Share price | $1.97 | $2.56 |
| Market cap | $274.89M | $281.02M |
| 1-day change | +3.14% | -2.66% |
| YTD return | -3.90% | -27.07% |
| 1-year return | +18.67% | -30.25% |
| 5-year return | -82.99% | -90.83% |
| EPS (TTM) | $-0.43 | $-0.17 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.61 | $5.45 |
| 52-week low | $1.33 | $2.42 |
| Distance from 52-week high | -24.52% | -53.03% |
| Analyst consensus | none | buy |
| Avg. price target upside | +204.57% | +232.03% |
| Average volume | 652.84K | 1.67M |
| Shares outstanding | 139.54M | 109.77M |
| Employees | 35 | 202 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IKT has outperformed RCKT by 48.9 percentage points over the past year.
About Inhibikase Therapeutics
IKT stock →Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 35 employees
About Rocket Pharmaceuticals
RCKT stock →Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases in the United States. It develops in vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), which is in Phase 2 trial; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), which is in phase 1; and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is a form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart, which is in preclinical stage.
Health Care · Biotechnology: Pharmaceutical Preparations · 202 employees
IKT vs RCKT FAQ
Which is bigger, Inhibikase Therapeutics or Rocket Pharmaceuticals?
Rocket Pharmaceuticals (RCKT) is larger, with a market capitalization of $281.02M compared with $274.89M for Inhibikase Therapeutics (IKT).
Which stock has performed better over the past year, IKT or RCKT?
IKT returned +18.67% over the past 12 months, compared with -30.25% for RCKT (price return, excluding dividends). Past performance does not predict future results.
Are Inhibikase Therapeutics and Rocket Pharmaceuticals in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Inhibikase Therapeutics and Biotechnology: Pharmaceutical Preparations for Rocket Pharmaceuticals.